Company intelligence / Profile preview

GreenHills

Vienna, Vienna, Austria

Ownership: Private
Development stage: Other

Overview

Avir Green Hills Biotechnology was a private Austrian biopharmaceutical company focused on developing innovative vaccines against viral infections and cancer. Its best-known programs were intranasal live attenuated influenza vaccines based on a delta NS1 platform, including candidates such as FLUVACCdelNS1, GHB16L2, and GHB04L1. The company advanced at least one influenza vaccine candidate into Phase 1/2 and Phase 2 development. Historical sources describe the company as headquartered in Vienna and financed through a mix of venture capital, grants, and founder capital. However, the company appears to have ceased operations and entered liquidation in 2012, so it is not an active operating biotech today.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineLive attenuated vaccine
Industry: Biotech

Beyond the preview

Go deeper on GreenHills.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GreenHills.

Explore the full profile